> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Jazz Lifts 2026 Revenue Outlook To $4.775 Billion–$4.85 Billion Despite $754 Million Actio Charge
- URL: https://www.bullished.co/jazz-lifts-2026-revenue-outlook-to-4-775-billion-4-85-billion-despite-754-million-actio-f11069a0/
- Published: 2026-11-02T21:28:13.000Z
- Updated: 2026-11-02T21:28:13.000Z
- Description: Record third-quarter revenue of $1,243.0 million met a $483.4 million net loss driven by acquired research expense.
- Author: Matteo Parrino
- Tags: Deals, JAZZ, Industry: Healthcare

[Jazz Pharmaceuticals](https://www.bullished.co/tag/jazz/), the rare-disease drugmaker behind Xywav and Epidiolex, raised its 2026 revenue guidance to [$4.775 billion to $4.85 billion](https://www.sec.gov/Archives/edgar/data/0001232524/000123252426000056/a3q26earningsrelease.htm?ref=bullished.co) after record third-quarter sales, even as a $754 million charge for its Actio Biosciences deal produced a quarterly loss. The company reported the results Monday.

## Record sales, a $483.4 million loss

Total revenues reached $1,243.0 million, up 10% from $1,126.1 million a year earlier. Jazz called it a record quarter, with higher sales of Xywav, Zepzelca and Ziihera, plus Modeyso, which was not on the market for the full year-earlier quarter.

The bottom line went the other way: a net loss of $483.4 million, or $7.48 per share, against net income of $251.4 million a year earlier. Acquired in-process research and development expense of $754 million, the value assigned to ABS-1230 in the Actio deal, cost $11.32 per share on a standard-accounting basis.

On an adjusted basis the quarter showed a loss of $3.88 per share versus earnings of $8.13 a year earlier. The company said the charge hit adjusted results by $11.03 per share. For the first nine months, adjusted earnings were $8.23 per share, up from $1.63.

The new guidance compares with $4.6 billion to $4.75 billion given on August 3\. The standard-accounting effective tax rate range moved to 20% to 30% from 0% to 10%, which the company tied to the Actio charge.

## Xywav and oncology carry the quarter

Jazz develops and sells medicines for rare diseases across sleep disorders, epilepsy and cancer. Xywav net sales rose 12% to [$483 million](https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2026-financial-results-302926800.html?ref=bullished.co), with about 425 net patient adds and roughly 17,550 active patients exiting the quarter.

Oncology revenue rose to $387.1 million from $287.8 million. Zepzelca sales climbed 32% to $104 million and Modeyso reached $61 million. Ziihera sales were [$21 million](https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2026-financial-results-302926800.html?ref=bullished.co) after its August 25 FDA approval for first-line HER2-positive gastroesophageal adenocarcinoma.

Epidiolex and Epidyolex sales slipped 2% to $295 million, which the company attributed to lower U.S. gross-to-net deductions a year earlier and wholesaler buying patterns. Xyrem sales fell to $31.2 million from $35.7 million.

## Cash, notes and the Actio pipeline

In the third quarter Jazz privately placed $1.25 billion of 1.875% exchangeable senior notes due 2032 and repurchased $225 million of shares. In October its board approved a new buyback of up to $500 million. At September 30, cash and investments were $2.9 billion against $5.6 billion of long-term debt principal.

Jazz closed the Actio deal in September. ABS-1230 is a potential first-in-class therapy for KCNT1-related epilepsy, and the company expects to present initial patient data at a medical meeting in the fourth quarter.

The FDA's target action date for Jazz's oral cannabidiol capsule application is April 16, 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Jazz Pharmaceuticals plc (JAZZ)](https://www.sec.gov/Archives/edgar/data/0001232524/000123252426000056/jazz-20261102.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a3q26earningsrelease.htm — Jazz Pharmaceuticals plc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001232524/000123252426000056/a3q26earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Jazz's Actio buyout gives rise to Setara with $90M series A](https://www.fiercebiotech.com/biotech/setara-raises-90m-series-carrying-actio-torch-following-jazz-acquisition?ref=bullished.co) — fiercebiotech.com
- [With Setara, the team behind Actio opens its second act | BioPharma Dive](https://www.biopharmadive.com/news/setara-actio-charcot-marie-tooth-ion-channel-drugs/873227/?ref=bullished.co) — biopharmadive.com
- [Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2026-financial-results-302926800.html?ref=bullished.co) — prnewswire.com

### More on Jazz Pharmaceuticals

- [Jazz Pharmaceuticals Expects $755 Million Actio Charge To Cut Third-Quarter EPS By About $11.00](https://www.bullished.co/jazz-pharmaceuticals-expects-755-million-actio-charge-to-cut-third-quarter-eps-by-about-11-306d13b0/)
- [Jazz Pharmaceuticals' Chief Commercial Officer Samantha Pearce Plans To Retire By June 30, 2027](https://www.bullished.co/jazz-pharmaceuticals-chief-commercial-officer-samantha-pearce-plans-to-retire-by-june-30-8227c8a6/)

[All Jazz Pharmaceuticals (JAZZ) coverage →](https://www.bullished.co/tag/jazz/)